Gus Cardenas - Longboard Pharmaceuticals VP Assurance

Insider

Gus Cardenas is VP Assurance of Longboard Pharmaceuticals
Phone858 789 9283
Webhttps://www.longboardpharma.com

Longboard Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.3072) % which means that it has lost $0.3072 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4666) %, meaning that it created substantial loss on money invested by shareholders. Longboard Pharmaceuticals' management efficiency ratios could be used to measure how well Longboard Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Longboard Pharmaceuticals currently holds 475 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Longboard Pharmaceuticals has a current ratio of 11.71, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Longboard Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Mark DudleyInstil Bio
N/A
Michael MBAChampions Oncology
N/A
MD FACPNextCure
71
MBA MBASensei Biotherapeutics
52
Eric RojasStoke Therapeutics
N/A
Dawn GiangiulioDesign Therapeutics
N/A
CPA CPAStoke Therapeutics
63
Sumita JDInstil Bio
50
Eric LindquistCelcuity LLC
N/A
Kristina ZambourasC4 Therapeutics
N/A
Thomas SchwerzmannMolecular Partners AG
N/A
Bronson CrouchInstil Bio
52
Dabt PhCelcuity LLC
67
Jeffrey EcsedyIkena Oncology
55
Michelle ZhangIkena Oncology
N/A
David HanleyNuvation Bio
55
Kim BlickenstaffNuvation Bio
68
Joan WoodStoke Therapeutics
N/A
Ellen MBAWerewolf Therapeutics
48
Nathanael GrayC4 Therapeutics
N/A
Lauren WhiteC4 Therapeutics
N/A
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California. Longboard Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 21 people. Longboard Pharmaceuticals (LBPH) is traded on NASDAQ Exchange in USA and employs 50 people.

Management Performance

Longboard Pharmaceuticals Leadership Team

Elected by the shareholders, the Longboard Pharmaceuticals' board of directors comprises two types of representatives: Longboard Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Longboard. The board's role is to monitor Longboard Pharmaceuticals' management team and ensure that shareholders' interests are well served. Longboard Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Longboard Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Dewey McLin, VP Affairs
Jodi Parsons, VP Affairs
Chadwick MPH, Executive Operations
Steven JD, Head Counsel
Randall MD, Executive Officer
Nuggehally Srinivas, VP Pharmacometrics
Megan Knight, Head Relations
Anne Danks, VP Development
Marco Peters, VP Science
Kevin Lind, CEO and President
Gus Cardenas, VP Assurance

Longboard Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Longboard Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Other Consideration for investing in Longboard Stock

If you are still planning to invest in Longboard Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Longboard Pharmaceuticals' history and understand the potential risks before investing.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Valuation
Check real value of public entities based on technical and fundamental data
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals